Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Vertex Pharmaceuticals Incorporated246 enrolled

Overview

Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

246

Conditions

Cystic Fibrosis

Interventions

LUM/IVADRUG

Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age). LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older).

LUM/IVADRUG

LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: Subjects entering the Treatment Cohort must meet both of the following criteria: * Completed study visits up to Week 24 of Study 109 or Week 26 of Study 011B and did not permanently discontinue treatment * Willing to remain on a stable CF medication through the Safety Follow-up Visit. Subjects entering the Observational Cohort must meet 1 of the following criteria: * Completed 24 weeks of study drug treatment in Study 109 or completed 24 weeks of study drug treatment and the Week 26 Safety Follow up in Study 011B. * Received at least 4 weeks of study drug and completed visits up to Week 24 of Study 109 or Week 26 of Study 011B. Exclusion Criteria (Treatment Cohort Only): * History of any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject (e.g., cirrhosis with portal hypertension). * Pregnant and nursing females. * Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements. * History of drug intolerance in the prior study that would pose an additional risk to the subject in the opinion of investigator * History of poor compliance with study drug and/or procedure in the previous study as deemed by the investigator. * Participation in an investigational drug trial (including studies investigating lumacaftor and/or ivacaftor).

Locations (60)

Outcomes

Primary Outcomes

Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Time frame: Day 1 up to Week 100

Secondary Outcomes

Absolute Change in Lung Clearance Index (LCI) 2.5

LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

Time frame: From Parent Study Baseline at Week 96

Absolute Change in Sweat Chloride

Sweat samples were collected using an approved collection device.

Time frame: From Parent Study Baseline at Week 96

Absolute Change in Body Mass Index (BMI)

BMI was defined as weight in kilograms divided by height in square meter (m\^2).

Time frame: From Parent Study Baseline at Week 96

Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame: From Parent Study Baseline at Week 96

Observational Cohort: Safety as Assessed by Serious Adverse Events (SAEs)

Time frame: Day 1 up to Week 100

Absolute Change in LCI 5.0

LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Birmingham, Alabama, United States

Unnamed facility

Tucson, Arizona, United States

Unnamed facility

Long Beach, California, United States

Unnamed facility

Palo Alto, California, United States

Unnamed facility

Aurora, Colorado, United States

Unnamed facility

Wilmington, Delaware, United States

Unnamed facility

Jacksonville, Florida, United States

Unnamed facility

Orlando, Florida, United States

Unnamed facility

Atlanta, Georgia, United States

Unnamed facility

Chicago, Illinois, United States

...and 50 more locations

Time frame: From Parent Study Baseline at Week 96

Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame: From Parent Study Baseline at Week 96

Relative Change in ppFEV1

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame: From Parent Study Baseline at Week 96

Absolute Change in BMI-for-age Z-score

BMI was defined as weight in kilograms divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame: From Parent Study Baseline at Week 96

Absolute Change in Weight

Time frame: From Parent Study Baseline at Week 96

Absolute Change in Weight-for-age Z-score

z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame: From Parent Study Baseline at Week 96

Absolute Change in Height

Time frame: From Parent Study Baseline at Week 96

Absolute Change in Height-for-age Z-score

Time frame: From Parent Study Baseline at Week 96

Absolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score

The TSQM measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed in the total domain score, which ranges from 0 to 100, where higher scores indicate greater satisfaction.

Time frame: From Parent Study Baseline at Week 96

Time-to-first Pulmonary Exacerbation

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame: From Parent Study Baseline through Week 96

Percentage of Participants Having At Least 1 Pulmonary Exacerbation Event

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame: From Parent Study Baseline through Week 96

Number of Pulmonary Exacerbation Events Per Patient-year

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame: From Parent Study Baseline through Week 96

Rate of Change in LCI 2.5

Rate of change analysis evaluates the change in LCI 2.5 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.

Time frame: Day 15 after first dose of LUM/IVA through Week 96

Rate of Change in LCI 5.0

Rate of change analysis evaluates the change in LCI 5.0 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.

Time frame: Day 15 after first dose of LUM/IVA through Week 96

Rate of Change in ppFEV1

Rate of change analysis evaluates the change in ppFEV1 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.

Time frame: Day 15 after first dose of LUM/IVA through Week 96

Treatment Period 2: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Time frame: Day 1 up to Week 168